Escitalopram
Product Images NDC 68258-7128

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Escitalopram (NDC 68258-7128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ndc 68258-7128-xx (Ndc 68258 7128 Xx West Ward)

Ndc 68258-7128-xx (Ndc 68258 7128 Xx West Ward)
This is a bulk source data of Escitalopram Oxalate tablets, which are scored, round, white, and film-coated. They are dispensed in a tight/light-resistant container and each film-coated tablet contains escitalopram oxalate USP equivalent to 10 mg escitalopram base. The lot number is indicated as XXXXXX, and the pedigree number is 0395563. The tablets are to be taken orally once daily in the morning or evening, as directed by a physician, with or without food, and it is recommended not to use them in combination with MAOIs or alcohol. It could cause drowsiness, and they should be stored at 68°-77° F. The manufacturer is West-Ward Pharmaceutical Corp, located in Eatontown, NJ 07724, and it is distributed by DispenseQuick, Santa Ana, CA 92704.*
FDA Label Image

Table 1 (Escitalopram 1)

Table 1 (Escitalopram 1)
FDA Label Image

Table 2 (Escitalopram 2)

Table 2 (Escitalopram 2)
This is a chart (Table 2) that shows the treatment-emergent adverse reactions observed in patients with major depressive disorder who received Escitalopram Oxalate. The adverse reactions are grouped according to several systems in the body, including the autonomic nervous system, the central and peripheral nervous system, the respiratory system, the gastrointestinal system, and the urogenital system. Some of the observed reactions include sweating, dizziness, constipation, indigestion, decreased appetite, and ejaculation disorders. The denominator used for each adverse reaction varies depending on the specific reaction.*
FDA Label Image

Table 3 (Escitalopram 3)

Table 3 (Escitalopram 3)
This is a table presenting treatment emergent adverse reactions observed in patients with generalized anxiety disorder who were administered Escitalopram oxalate Plash. The table shows the percentage frequency of adverse events with 7% or higher compared to the placebo group. The adverse reactions are divided into different categories, including neurological, gastrointestinal, musculoskeletal, and respiratory disorders, among others. The table presents the data separately for males and females, and it includes the total number of participants used in the analysis.*
FDA Label Image

Table 4 (Escitalopram 4)

Table 4 (Escitalopram 4)
The table lists the incidence of common adverse reactions for patients with major depressive disorder. Various factors such as placebo, 10mg/day, and 20mg/day of Escitalopram were tested against each other. The reactions mentioned in the table include dry mouth, somnolence, sweating, constipation, fatigue, and indigestion.*
FDA Label Image

Table 5 (Escitalopram 5)

Table 5 (Escitalopram 5)
FDA Label Image

Esc Chem Structure (Escitalopram 6)

Esc Chem Structure (Escitalopram 6)
CHO is a chemical compound with the molecular formula CH_FN, - CH.0 and molecular weight of 414.40. Its structural formula is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.